Registrer deg | Logg på | FAQ      [?] 
Recent | Unread | Search | Authors | Tags | Export

pjaspers inhibitor [67 articles]

Artikler nylig sendt til pjaspers bibliotek klassifisert med nøkkelordet inhibitor. You can also see everyone's inhibitor.
  • ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
    Proc Natl Acad Sci U S A, Vol. 102, No. 10. (8 March 2005), pp. 3788-3793.
    by JA Engelman, PA Jänne, C Mermel, J Pearlberg, T Mukohara, C Fleet, K Cichowski, BE Johnson, LC Cantley
    posted to akt erbb3 inhibitor iressa nsclc by pjasper on 2007-05-22 18:40:08 as **
  • Features of selective kinase inhibitors.
    Chem Biol, Vol. 12, No. 6. (June 2005), pp. 621-637.
    by ZA Knight, KM Shokat
    posted to inhibitor review by pjasper on 2007-05-10 20:55:43 as ***** along with 3 people Yanno anwazo seancutler
  • Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site.
    J Biol Chem, Vol. 272, No. 37. (12 September 1997), pp. 23247-23254.
    by CL Arteaga, TT Ramsey, LK Shawver, CA Guyer
    posted to egfr erbb2 inactive_dimer inhibitor by pjasper on 2007-05-10 20:34:56 as *****
  • Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Cancer Res, Vol. 61, No. 15. (1 August 2001), pp. 5790-5795.
    by RB Lichtner, A Menrad, A Sommer, U Klar, MR Schneider
    posted to egfr inhibitor by pjasper on 2007-05-10 20:30:15 as *****
  • HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Cancer Res, Vol. 65, No. 10. (15 May 2005), pp. 4253-4260.
    by A Hirata, F Hosoi, M Miyagawa, S Ueda, S Naito, T Fujii, M Kuwano, M Ono
    posted to egfr erbb2 inhibitor iressa nsclc by pjasper on 2007-05-10 19:52:18 as ***** along with 1 person js229
  • T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies
    Cancer Immunology, Immunotherapy
    by Greta Garrido, Pablo Lorenzano, Belinda Sánchez, Irene Beausoleil, Daniel Alonso, Rolando Pérez, Luis Fernández
    posted to c225 cell egfr inhibitor t by pjasper on 2007-05-08 20:52:25 as **
  • Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Mol Cancer Res, Vol. 5, No. 4. (April 2007), pp. 393-401.
    by M Maegawa, K Takeuchi, E Funakoshi, K Kawasaki, K Nishio, N Shimizu, F Ito
    posted to c225 egfr erbb2 erbb3 inhibitor nsclc by pjasper on 2007-05-08 20:50:27 as **
  • The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Bioorg Med Chem Lett (19 March 2007)
    by Blaise Lippa, Goss S S Kauffman, Joel Arcari, Tricia Kwan, Jinshan Chen, William Hungerford, Samit Bhattacharya, Xumiao Zhao, Courtney Williams, Jun Xiao, Leslie Pustilnik, Chunyan Su, James D D Moyer, Ling Ma, Mary Campbell, Stefanus Steyn
    posted to erbb2 inhibitor by pjasper on 2007-05-08 20:46:17 as **
  • Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Oncologist, Vol. 12, No. 3. (March 2007), pp. 325-330.
    by LV Sequist
    posted to 2ndgeneration egfr inhibitor nsclc review by pjasper on 2007-05-08 20:37:49 as **
  • Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?
    Cancer Treat Rev (15 March 2007)
    by Barbara Fischer, Marin Marinov, Alexandre Arcaro
    posted to inhibitor review sclc by pjasper on 2007-05-08 19:05:26 as **
  • Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
    Cancer Cell, Vol. 11, No. 3. (March 2007), pp. 217-227.
    by CH Yun, TJ Boggon, Y Li, MS Woo, H Greulich, M Meyerson, MJ Eck
    posted to egfr inhibitor mutation review structure by pjasper on 2007-05-08 19:00:37 as ** along with 1 person and 1 group cursonivel1 cursonivel1
  • A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
    Proc Natl Acad Sci U S A, Vol. 104, No. 10. (6 March 2007), pp. 4071-4076.
    by AM Scott, FT Lee, N Tebbutt, R Herbertson, SS Gill, Z Liu, E Skrinos, C Murone, TH Saunder, B Chappell, AT Papenfuss, AM Poon, W Hopkins, FE Smyth, D MacGregor, LM Cher, AA Jungbluth, MW Brechbiel, R Murphy, AW Burgess, EW Hoffman, TG Johns, LJ Old
    posted to ch806 egfr inhibitor by pjasper on 2007-05-08 18:57:28 as **
  • Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
    Clin Cancer Res, Vol. 13, No. 5. (1 March 2007), pp. 1552-1561.
    by J Kurai, H Chikumi, K Hashimoto, K Yamaguchi, A Yamasaki, T Sako, H Touge, H Makino, M Takata, M Miyata, M Nakamoto, N Burioka, E Shimizu
    posted to c225 egfr inhibitor by pjasper on 2007-05-08 18:55:26 as **
  • HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
    Breast Cancer Research, Vol. 9 (02 March 2007), 205.
    by Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden, Sarah Bacus
    posted to erbb2 inhibitor by pjasper on 2007-05-08 18:50:28 as ** along with 1 person klu
  • Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy
    British Journal of Cancer, Vol. aop, No. current. (06 March 2007)
    by A Jimeno, P Kulesza, J Wheelhouse, A Chan, X Zhang, E Kincaid, R Chen, DP Clark, A Forastiere, M Hidalgo
    posted to egfr inhibitor mtor by pjasper on 2007-05-08 18:48:03 as **
  • Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
    Ann Oncol, Vol. 18, No. 4. (April 2007), pp. 752-760.
    by F Hirsch, M Varella-Garcia, F Cappuzzo, J McCoy, L Bemis, A Xavier, R Dziadziuszko, P Gumerlock, K Chansky, H West, A Gazdar, L Crino, D Gandara, W Franklin, P Bunn
    posted to amplification egfr inhibitor iressa nsclc by pjasper on 2007-05-08 18:46:53 as **
  • EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Crit Rev Oncol Hematol, Vol. 62, No. 1. (April 2007), pp. 53-61.
    by O Dassonville, A Bozec, JL Fischel, G Milano
    posted to antibody egfr inhibitor review by pjasper on 2007-05-08 18:36:54 as **
  • Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
    British Journal of Cancer, Vol. aop, No. current. (27 February 2007)
    by H Uramoto, T Mitsudomi
    posted to biomarker egfr inhibitor review by pjasper on 2007-05-08 18:35:58 as **
  • Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
    Mol Cancer Ther, Vol. 6, No. 2. (February 2007), pp. 667-674.
    by R Nahta, LX Yuan, Y Du, FJ Esteva
    posted to breast igf inhibitor lapatinib trastuzumab by pjasper on 2007-05-08 18:32:52 as **
  • The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR|[sol]|ERBB2 inhibitor HKI-272
    Oncogene, Vol. aop, No. current.
    by Y Minami, T Shimamura, K Shah, T Laframboise, KA Glatt, E Liniker, CL Borgman, HJ Haringsma, W Feng, BA Weir, AM Lowell, JC Lee, J Wolf, GI Shapiro, KK Wong, M Meyerson, RK Thomas, ,
    posted to erbb2 hki-272 inhibitor mutation by pjasper on 2007-05-08 18:31:24 as **
  • Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
    Cancer Science, Vol. 98, No. 3. (March 2007), pp. 357-363.
    by Uchida, Akiko, Hirano, Seiki, Kitao, Hiroyuki, Ogino, Atsuko, Rai, Kanmei, Toyooka, Shinichi, Takigawa, Nagio, Tabata, Masahiro, Takata, Minoru, Kiura, Katsuyuki, Tanimoto, Mitsune
    posted to activation egfr inhibitor mutation by pjasper on 2007-05-08 18:28:39 as **
  • HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks
    Breast Cancer Research, Vol. 9 (22 January 2007), 202.
    by Ralf Landgraf
    posted to erbb2 inhibitor review by pjasper on 2007-05-08 18:26:54 as **
  • p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
    Cancer Res, Vol. 67, No. 3. (1 February 2007), pp. 1163-1169.
    by JK Rho, YJ Choi, BY Ryoo, II Na, SH Yang, CH Kim, JC Lee
    posted to apoptosis inhibitor nsclc p53 tarceva by pjasper on 2007-05-08 18:24:35 as **
  • Combining an mTOR Antagonist and Receptor Tyrosine Kinase Inhibitors for the Treatment of Prostate Cancer.
    Cancer Biol Ther, Vol. 6, No. 2. (February 2007), pp. 195-201.
    by D Masiello, MG Mohi, NC McKnight, B Smith, BG Neel, SP Balk, GJ Bubley
    posted to inhibitor mtor prostate by pjasper on 2007-05-08 18:18:26 as **
  • Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Eur J Cancer, Vol. 43, No. 3. (February 2007), pp. 481-489.
    by A Reid, L Vidal, H Shaw, J de Bono
    posted to erbb inhibitor review by pjasper on 2007-05-08 18:11:37 as **
  • Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors.
    J Immunol, Vol. 178, No. 2. (15 January 2007), pp. 1021-1029.
    by K Furuuchi, A Berezov, T Kumagai, MI Greene
    posted to egfr inhibitor tetramer by pjasper on 2007-05-08 18:06:47 as **
  • Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
    Clin Cancer Res, Vol. 12, No. 24. (15 December 2006), pp. 7242-7251.
    by M Ono, M Kuwano
    posted to egfr inhibitor iressa review by pjasper on 2007-04-26 17:44:12 as **
  • Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor.
    FEBS Lett, Vol. 580, No. 20. (4 September 2006), pp. 4793-4800.
    by R Mandic, CJ Rodgarkia-Dara, L Zhu, BJ Folz, M Bette, E Weihe, A Neubauer, JA Werner
    posted to activation c225 inhibitor by pjasper on 2007-04-26 17:11:05 as **
  • Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
    Cancer Res, Vol. 66, No. 16. (15 August 2006), pp. 8163-8171.
    by KD Carey, AJ Garton, MS Romero, J Kahler, S Thomson, S Ross, F Park, JD Haley, N Gibson, MX Sliwkowski
    posted to inhibitor mutation tarceva by pjasper on 2007-04-26 17:08:30 as **
  • Epidermal growth factor receptor targeting in cancer.
    Semin Oncol, Vol. 33, No. 4. (August 2006), pp. 369-385.
    by J Mendelsohn, J Baselga
    posted to egfr inhibitor review by pjasper on 2007-04-25 22:10:25 as **
  • Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
    Cancer Res, Vol. 66, No. 15. (1 August 2006), pp. 7630-7638.
    by JJ Lammerts van Bueren, WK Bleeker, HO Bøgh, M Houtkamp, J Schuurman, JG van de Winkel, PW Parren
    posted to egfr inhibitor novel by pjasper on 2007-04-25 21:49:16 as **
  • Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
    Cancer Res, Vol. 66, No. 15. (1 August 2006), pp. 7708-7715.
    by MP Cunningham, H Thomas, Z Fan, H Modjtahedi
    posted to colon icr62 inhibitor iressa novel by pjasper on 2007-04-25 21:48:28 as **
  • Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by TJ Lynch, AA Adjei, PA Bunn, TG Eisen, J Engelman, GD Goss, DA Haber, JV Heymach, PA Jänne, BE Johnson, DH Johnson, RC Lilenbaum, M Meyerson, AB Sandler, LV Sequist, J Settleman, KK Wong, CS Hart
    posted to erbb inhibitor novel nsclc review by pjasper on 2007-04-25 21:47:09 as **
  • Her2-targeted therapies in non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by C Swanton, A Futreal, T Eisen
    posted to erbb2 inhibitor nsclc review by pjasper on 2007-04-25 21:46:05 as **
  • Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Clin Cancer Res, Vol. 12, No. 14 Pt 2. (15 July 2006)
    by JV Heymach, M Nilsson, G Blumenschein, V Papadimitrakopoulou, R Herbst
    posted to inhibitor novel nsclc review by pjasper on 2007-04-25 21:44:21 as **
  • Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.
    Int J Cancer, Vol. 119, No. 10. (15 November 2006), pp. 2455-2463.
    by OM Fattah, SM Cloutier, C Kündig, LM Felber, CM Gygi, P Jichlinski, HJ Leisinger, ER Gauthier, JP Mach, D Deperthes
    posted to apoptosis inhibitor peptabody by pjasper on 2007-04-25 21:43:24 as **
  • Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
    Cold Spring Harb Symp Quant Biol, Vol. 70 (2005), pp. 419-426.
    by DA Haber, DW Bell, R Sordella, EL Kwak, N Godin-Heymann, SV Sharma, TJ Lynch, J Settleman
    posted to inhibitor mutation review by pjasper on 2007-04-25 21:39:46 as **
  • HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
    Cancer Cell, Vol. 10, No. 1. (July 2006), pp. 25-38.
    by SE Wang, A Narasanna, M Perez-Torres, B Xiang, FY Wu, S Yang, G Carpenter, AF Gazdar, SK Muthuswamy, CL Arteaga
    posted to activation erbb2 inhibitor mutation resistance by pjasper on 2007-04-25 21:37:42 as **
  • Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
    Cancer Cell, Vol. 10, No. 1. (July 2006), pp. 39-50.
    by BB Zhou, M Peyton, B He, C Liu, L Girard, E Caudler, Y Lo, F Baribaud, I Mikami, N Reguart, G Yang, Y Li, W Yao, K Vaddi, AF Gazdar, SM Friedman, DM Jablons, RC Newton, JS Fridman, JD Minna, PA Scherle
    posted to adam erbb3 inhibitor nsclc by pjasper on 2007-04-25 21:37:16 as *****
  • Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Clin Cancer Res, Vol. 12, No. 13. (1 July 2006), pp. 4103-4111.
    by K Erjala, M Sundvall, TT Junttila, N Zhang, M Savisalo, P Mali, J Kulmala, J Pulkkinen, R Grenman, K Elenius
    posted to erbb2 erbb3 inhibitor iressa resistance by pjasper on 2007-04-25 21:06:38 as **
  • Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer.
    Clin Colorectal Cancer, Vol. 6, No. 1. (May 2006)
    by E Chu
    posted to egfr inhibitor panitumumab by pjasper on 2007-04-25 21:04:31 as **
  • Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.
    Exp Cell Res, Vol. 312, No. 15. (10 September 2006), pp. 2778-2790.
    by ML Jaramillo, Z Leon, S Grothe, B Paul-Roc, A Abulrob, M O'Connor McCourt
    posted to c225 endosome inhibitor internalization by pjasper on 2007-04-25 21:00:15 as **
  • Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo
    International Journal of Urology, Vol. 13, No. 5. (May 2006), pp. 587-592.
    by A Nagasaw, I Joj, I Mizokam, I Atsush, A Koshid, I Kiyosh, A Yoshid, I Se, O Nait, O Kenichir, I Namik, O Miki
    posted to erbb2 inhibitor novel by pjasper on 2007-04-25 20:39:35 as **
  • Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
    Clin Cancer Res, Vol. 12, No. 21. (1 November 2006), pp. 6326-6330.
    by F Meric-Bernstam, MC Hung
    posted to erbb2 inhibitor review by pjasper on 2007-04-25 20:25:04 as **
  • The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.
    J Biol Chem, Vol. 282, No. 5. (2 February 2007), pp. 2840-2850.
    by HK Gan, F Walker, AW Burgess, A Rigopoulos, AM Scott, TG Johns
    posted to ag1478 dimerization inhibitor by pjasper on 2007-04-25 20:21:10 as **
  • Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors
    BMC Genomics, Vol. 7 (10 November 2006), 289.
    by Justin M Balko, Anil Potti, Christopher Saunders, Arnold Stromberg, Eric B Haura, Esther P Black
    posted to genomics inhibitor nsclc by pjasper on 2007-04-25 20:18:26 as **
  • Compensatory increases in Her-2/neu activation in response to EGFR tyrosine kinase inhibition in colon cancer cell lines.
    J Surg Res, Vol. 136, No. 2. (December 2006), pp. 227-231.
    by PA Learn, N Krishnegowda, J Talamantez, MS Kahlenberg
    posted to color erbb2 inhibitor by pjasper on 2007-04-25 20:03:27 as **
  • Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Clin Cancer Res, Vol. 12, No. 20 Pt 1. (15 October 2006), pp. 6186-6193.
    by TW Wong, FY Lee, C Yu, FR Luo, S Oppenheimer, H Zhang, RA Smykla, H Mastalerz, BE Fink, JT Hunt, AV Gavai, GD Vite
    posted to bms-599626 egfr erbb2 inhibitor by pjasper on 2007-04-25 20:00:02 as **
  • Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
    Int J Cancer, Vol. 120, No. 2. (15 January 2007), pp. 329-336.
    by H Novak, R Noy, K Oved, D Segal, WS Wels, Y Reiter
    posted to c225 immunity inhibitor by pjasper on 2007-04-25 19:58:58 as **
  • Surface Plasmon Resonance Investigations of Human Epidermal Growth Factor Receptor 2
    Applied Spectroscopy, Vol. 60, No. 9. (September 2006), pp. 994-1003.
    by Martin, , Sullivan, , Walker, , Hawk, , Sullivan, , Noe,
    posted to erbb2 inhibitor structure by pjasper on 2007-04-25 19:46:51 as **
    • NB: Du kan sitere denne siden som: http://www.citeulike.org/user/pjasper/tag/inhibitor

    Result page: 1 2 Next RIS BibTeX
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.